Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2023

Summary of Significant Accounting Policies

Schedule of earnings per share, basic and diluted

		Three Months Ended September 30,								Nine Months Ended September 30,
		2023				2022				2023				2022

Net loss		$	(1,719,211	)		$	(2,424,586	)		$	(5,660,717	)		$	(7,941,311	)

Weighted-average basic and diluted common shares			3,189,034				767,275				2,301,360				663,892

Basic and diluted net loss per common share		$	(0.54	)		$	(3.16	)		$	(2.46	)		$	(11.96	)

Schedule of potentially diluted basic earnings

		As of September 30,
		2023				2022
Common Stock options			102,074				66,020
Common Stock warrants			4,643,555				437,113
Total potentially dilutive securities			4,745,629				503,133